KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

Linmiao Jiang, Martin Dreyling, Olivier Hermine, Ulrich Mansmann, Jan Walewski, Vincent Ribrag, Catherine Thieblemont, Christiane Pott, Emmanuel Bachy, Pierre Feugier, Kai Hübel, Martin Schumacher, Eva Hoster

Br J Haematol 206(1) 159-166

PMID39442921
PMCIDPMC11739754
DOI10.1111/bjh.19854
发表日期2024-10-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional survival captures their future survival probability. We investigated conditional overall and failure-free survival in 473 younger mantle cell lymphoma (MCL) patients from a randomized phase III trial comparing immunochemotherapies R-CHOP and alternating R-CHOP/R-DHAP before autologous transplantation. Using conditional Kaplan-Meier method and Cox regression, we estimated subsequent survival of patients who had survived 1-8 years, considering MIPI, Ki-67, and treatment failure status. Starting at a lower level, R-CHOP patients only showed increasing subsequent survival as they survived longer (5-year conditional survival: 72% and 81% after surviving 1 and 7 years), while R-CHOP/R-DHAP patients had stable future survival over time (77% and 78%). The prognostic value of MIPI diminished after 3 years in R-CHOP patients but remained unchanged after R-CHOP/R-DHAP. Patients with treatment failure had markedly inferior survival compared with those in ongoing remission, regardless of the time survived. The longer patients remained in remission, the longer they would stay free of treatment failures. Our results enable personalized counselling for younger MCL patients by offering dynamic prognosis and underscore the importance of highly effective first-line treatment to improve survival.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 1

Kaplan–Meier plots of conditional overall survival in (A) R‐CHOP group (B) R‐DHAP group.

A

conditional overall survival

FIGURE 1 · Panel A

quality_warning 待 EXE 对齐 预期 12 条 已提取 8 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 12 条,实际恢复 8 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

conditional overall survival

FIGURE 1 · Panel B

quality_warning 待 EXE 对齐 预期 12 条 已提取 7 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 12 条,实际恢复 7 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 2Kaplan–Meier estimates of 3‐ and 5‐year (A) conditional overall survival probabilities and (B) conditional failure‐free survival probabilities with 95% confidence intervals in R‐CHOP and R‐DHAP groups.
非 KM Figure
FIGURE 3Estimates of 5‐year conditional overall survival probabilities with 95% confidence intervals from Cox regression models for (A) MIPI groups (B) treatment failure groups (C) Ki‐67 groups ( N = 290) (D) MIPI and treatment failure groups in R‐CHOP group (E) MIPI and treatment failure groups in R‐DHAP group. MIPI, Mantle Cell Lymphoma International Prognostic Index.
非 KM Figure
FIGURE 4Effects of MIPI score and treatment failure on conditional overall survival at each prediction time point in (A) R‐CHOP group (B) R‐DHAP group. MIPI, Mantle Cell Lymphoma International Prognostic Index; numbers on the left are prediction time in years from study registration; hazard ratios and corresponding 95% confidence intervals are derived from multivariate Cox regression models; the grey vertical line denotes hazard ratio of 1.
非 KM Figure